HONOLULU (AP) ? A representative for Alex O'Loughlin says the "Hawaii Five-0" star is taking time away from the show to get treated for problems related to pain medication.
Rachael Wesolowski says in a report by the Honolulu Star-Advertiser that O'Loughlin " is taking a short break to receive supervised treatment for prescription pain medication due to a recent shoulder injury."
Series producer CBS Television Studios and O'Loughlin representatives declined to comment on the nature of O'Loughlin's injuries or his treatment.
O'Loughlin, who portrays crime fighter Steve McGarrett, is known for doing many of his own stunts on the action-packed show. The paper says he reportedly will be absent for at least one episode.
CBS says in a statement that "everyone at CBS Television Studios and 'Hawaii Five-0' wishes him well and we look forward to his return."
[unable to retrieve full-text content]Reuters - Neiman Marcus Group Inc reported a higher quarterly profit on Friday as high-end shoppers snapped up more of the luxury department store operator's expensive designer dresses, shoes and handbags during the holiday period.
[unable to retrieve full-text content]Reuters - Five people have been killed in tornado-related fatalities in the state of Kentucky, Governor Steve Beshear's office said on Friday.
Whether it is Sacramento?s wet season, which lasts from October to April, or the middle of the summer, you want your HVAC (Heating, Ventilation, and Air Conditioning) system to keep your home at a comfortable temperature at all times. Additionally, a heating and air conditioning system that is not functioning at peak performance can cost you more money in the form of increased energy bills. To avoid outrageous repair bills and to reduce your energy costs, it is best to have a HVAC contractor maintain your system. Here are a few tips for hiring a reputable heating system services Sacramento contractor.
Licensing is an important qualification for a heating and air conditioning system services Sacramento contractor. In California, an HVAC contractor is required to be licensed to work in the state.
This protects you from fraud and other problems that may arise when working with an unlicensed contractor. The government agency that handles this is the Department of Consumer Affairs Contractors State License Board. You can use their website to check the status of an HVAC contractor. This also where you would go for help if you have a problem with a licensed contractor and you are not able to come to a solution working with the person directly.
Another important qualification is experience. While licensing protects you from fraud and gives you legal recourse should something go wrong, you want to work with a heating system services Sacramento contractor who knows what they are doing. The last thing you want is to have an unskilled contractor break your HVAC system and causing you to spend more money repairing it.
Take time to interview the contractor and ask about their education and experience. Request the names and contact information for previous customers and contact those customers to see how the contractor performed.
If you are hiring a heating system services Sacramento contractor to help you reduce your energy bills, then they should be knowledgeable about the various Energy Star guidelines that can help you trim expenses. Good contractors will be able to provide you with energy saving tips as well as recommend products to reduce energy consumption. Typically, the contractor will perform a home evaluation and give their recommendations afterwards. If they don?t do this, then you will want to keep shopping around. A contractor who makes recommendations without evaluating your home is guaranteed to give advice that does nothing to help you but ensures they get as much money from you as possible.
[unable to retrieve full-text content]AP - Yelp is set to make its stock market debut Friday after pricing its initial public offering above its targeted range, a sign of strong investor demand for a slice of the 8-year-old online reviews site that has yet to turn a profit.
In the honeymoon stage of your marriage, every single love song on the car radio is just common sense. It doesn?t matter what your sweet heart does, they can never be wrong. Sad to say, this is going to change and you?ll start to see things you never observed in the past. If you?ve lived as a couple prior to getting married, you most likely are in a better position to get beyond this level, but that still doesn?t mean you?re safe and sound.
One of the most common marriage problems encountered by husbands and wives is disillusionment. Many enter in the relationship in a honeymoon fuzz and it may keep them from seeing the negatives. Now, we?re not saying that you do not know who your partner is. It?s going to be about the little things that you might not have seen in the past. Typically, lovers can power through this with little trouble. Nonetheless, other folks can turn it into something more substantial. It might even lead to unhappy marriage.
It?s this disillusionment that can lead a partner to feel as if they?ve lost love with their partner. And it will go bad rapidly. If this struggle is not handled right, it can lead to plenty of problems. Your intimacy can suffer and it may have an effect on communication. This can cause a great deal of unhappy marriage signs.
The good news here is that it can be easy to make your significant other love you again. You may convey your feelings through your words and through contact. You may confirm your spouse through the little things. Make positive you show your partner how you value them. If you partner fixes the pc for you, you could say something such as ?Thank you so much, I would not have been capable of much work without my laptop or computer. Thanks, you?re really great at this.? Touch is also Key. You may convey emotions through simple and harmless skin contact. You can hold your lover?s hand or you can kiss them on the cheek or give them a toasty hug.
New treatment using inhaled interferon may improve lung function in pulmonary fibrosisPublic release date: 29-Feb-2012 [ | E-mail | Share ]
Contact: Cathia Falvey cfalvey@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle -- Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article on inhaled interferon-gamma (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919) is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.
Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.
The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled "Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis." (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919)
"There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years," says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. "The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy."
###
About the Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) is an authoritative peer-reviewed journal published bimonthly in print and online. It is the Official Publication of the International Society for Aerosols in Medicine (www.isam.org). The Journal is the only authoritative publication delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. Topics covered include airway reactivity and asthma treatment, inhalation of particles and gases in the respiratory tract, toxic effects of inhaled agents, and aerosols as tools for studying basic physiologic phenomena. Complete tables of content and a sample issue may be viewed on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.
About the Company
Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Pediatric Allergy, Immunology, and Pulmonology, High Altitude Medicine & Biology, and Microbial Drug Resistance. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available online at Mary Ann Liebert, Inc. (http://www.liebertpub.com)
Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: 914-740-2100
800-M-LIEBERT
Fax: 914-740-2101
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
New treatment using inhaled interferon may improve lung function in pulmonary fibrosisPublic release date: 29-Feb-2012 [ | E-mail | Share ]
Contact: Cathia Falvey cfalvey@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle -- Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article on inhaled interferon-gamma (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919) is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.
Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.
The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled "Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis." (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919)
"There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years," says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. "The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy."
###
About the Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) is an authoritative peer-reviewed journal published bimonthly in print and online. It is the Official Publication of the International Society for Aerosols in Medicine (www.isam.org). The Journal is the only authoritative publication delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. Topics covered include airway reactivity and asthma treatment, inhalation of particles and gases in the respiratory tract, toxic effects of inhaled agents, and aerosols as tools for studying basic physiologic phenomena. Complete tables of content and a sample issue may be viewed on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.
About the Company
Mary Ann Liebert, Inc. (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Pediatric Allergy, Immunology, and Pulmonology, High Altitude Medicine & Biology, and Microbial Drug Resistance. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available online at Mary Ann Liebert, Inc. (http://www.liebertpub.com)
Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: 914-740-2100
800-M-LIEBERT
Fax: 914-740-2101
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vE7BW4f7B2NQk5YEpWyu2vQ6_BoaO_EHSGVjznXBfJ8CmPTcoALhkGlJoSEfpKrZpg-vRjUjllQ7FrnK7J2HtoLIUpZ3jkrYM4_PRqvvc=s0-d){kind=small}
Public release date: 29-Feb-2012
Share ]